Login to Your Account



Ferrokin redux? Wilson Therapeutics raises $40M for copper chelator

By Cormac Sheridan
Staff Writer

Wednesday, April 16, 2014
Wilson Therapeutics AB raised $40 million in a series B round to fund clinical development of WTX101 in Wilson's disease, a genetic disorder characterized by pathological accumulations of copper.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription